Rectal steroids suppress bone formation in patients with colitis
Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
ROBINSON, R. J. [verfasserIn] IQBAL, S. J. [verfasserIn] WHITAKER, R. P. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford BSL: Blackwell Science ; 1997 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2008 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Alimentary pharmacology & therapeutics - Oxford : Blackwell Science, 1987, 11(1997), 1, Seite 0 |
| Übergeordnetes Werk: |
volume:11 ; year:1997 ; number:1 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-2036.1997.123294000.x |
|---|
| Katalog-ID: |
NLEJ242219195 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242219195 | ||
| 003 | DE-627 | ||
| 005 | 20230505185203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s1997 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-2036.1997.123294000.x |2 doi | |
| 035 | |a (DE-627)NLEJ242219195 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a ROBINSON, R. J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rectal steroids suppress bone formation in patients with colitis |
| 264 | 1 | |a Oxford BSL |b Blackwell Science |c 1997 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. | ||
| 533 | |d 2008 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2008|||||||||| | ||
| 700 | 1 | |a IQBAL, S. J. |e verfasserin |4 aut | |
| 700 | 1 | |a WHITAKER, R. P. |e verfasserin |4 aut | |
| 700 | 1 | |a ABRAMS, K. |4 oth | |
| 700 | 1 | |a MAYBERRY, F. |4 oth | |
| 773 | 0 | 8 | |i In |t Alimentary pharmacology & therapeutics |d Oxford : Blackwell Science, 1987 |g 11(1997), 1, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926529 |w (DE-600)2003094-0 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:1997 |g number:1 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 1997 |e 1 |h 0 | ||
| author_variant |
r j r rj rjr s j i sj sji r p w rp rpw |
|---|---|
| matchkey_str |
article:13652036:1997----::etltrisupesoeomtoipte |
| hierarchy_sort_str |
1997 |
| publishDate |
1997 |
| allfields |
10.1046/j.1365-2036.1997.123294000.x doi (DE-627)NLEJ242219195 DE-627 ger DE-627 rakwb ROBINSON, R. J. verfasserin aut Rectal steroids suppress bone formation in patients with colitis Oxford BSL Blackwell Science 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| IQBAL, S. J. verfasserin aut WHITAKER, R. P. verfasserin aut ABRAMS, K. oth MAYBERRY, F. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 11(1997), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:11 year:1997 number:1 pages:0 http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 1997 1 0 |
| spelling |
10.1046/j.1365-2036.1997.123294000.x doi (DE-627)NLEJ242219195 DE-627 ger DE-627 rakwb ROBINSON, R. J. verfasserin aut Rectal steroids suppress bone formation in patients with colitis Oxford BSL Blackwell Science 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| IQBAL, S. J. verfasserin aut WHITAKER, R. P. verfasserin aut ABRAMS, K. oth MAYBERRY, F. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 11(1997), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:11 year:1997 number:1 pages:0 http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 1997 1 0 |
| allfields_unstemmed |
10.1046/j.1365-2036.1997.123294000.x doi (DE-627)NLEJ242219195 DE-627 ger DE-627 rakwb ROBINSON, R. J. verfasserin aut Rectal steroids suppress bone formation in patients with colitis Oxford BSL Blackwell Science 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| IQBAL, S. J. verfasserin aut WHITAKER, R. P. verfasserin aut ABRAMS, K. oth MAYBERRY, F. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 11(1997), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:11 year:1997 number:1 pages:0 http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 1997 1 0 |
| allfieldsGer |
10.1046/j.1365-2036.1997.123294000.x doi (DE-627)NLEJ242219195 DE-627 ger DE-627 rakwb ROBINSON, R. J. verfasserin aut Rectal steroids suppress bone formation in patients with colitis Oxford BSL Blackwell Science 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| IQBAL, S. J. verfasserin aut WHITAKER, R. P. verfasserin aut ABRAMS, K. oth MAYBERRY, F. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 11(1997), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:11 year:1997 number:1 pages:0 http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 1997 1 0 |
| allfieldsSound |
10.1046/j.1365-2036.1997.123294000.x doi (DE-627)NLEJ242219195 DE-627 ger DE-627 rakwb ROBINSON, R. J. verfasserin aut Rectal steroids suppress bone formation in patients with colitis Oxford BSL Blackwell Science 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| IQBAL, S. J. verfasserin aut WHITAKER, R. P. verfasserin aut ABRAMS, K. oth MAYBERRY, F. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 11(1997), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:11 year:1997 number:1 pages:0 http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 1997 1 0 |
| source |
In Alimentary pharmacology & therapeutics 11(1997), 1, Seite 0 volume:11 year:1997 number:1 pages:0 |
| sourceStr |
In Alimentary pharmacology & therapeutics 11(1997), 1, Seite 0 volume:11 year:1997 number:1 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Alimentary pharmacology & therapeutics |
| authorswithroles_txt_mv |
ROBINSON, R. J. @@aut@@ IQBAL, S. J. @@aut@@ WHITAKER, R. P. @@aut@@ ABRAMS, K. @@oth@@ MAYBERRY, F. @@oth@@ |
| publishDateDaySort_date |
1997-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926529 |
| id |
NLEJ242219195 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242219195</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505185203.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1997 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.1997.123294000.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242219195</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">ROBINSON, R. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rectal steroids suppress bone formation in patients with colitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford BSL</subfield><subfield code="b">Blackwell Science</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">IQBAL, S. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">WHITAKER, R. P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">ABRAMS, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">MAYBERRY, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">11(1997), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:1997</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">1997</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
ROBINSON, R. J. |
| spellingShingle |
ROBINSON, R. J. Rectal steroids suppress bone formation in patients with colitis |
| authorStr |
ROBINSON, R. J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926529 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford BSL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2036 |
| topic_title |
Rectal steroids suppress bone formation in patients with colitis |
| publisher |
Blackwell Science |
| publisherStr |
Blackwell Science |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k a ka f m fm |
| hierarchy_parent_title |
Alimentary pharmacology & therapeutics |
| hierarchy_parent_id |
NLEJ243926529 |
| hierarchy_top_title |
Alimentary pharmacology & therapeutics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926529 (DE-600)2003094-0 |
| title |
Rectal steroids suppress bone formation in patients with colitis |
| ctrlnum |
(DE-627)NLEJ242219195 |
| title_full |
Rectal steroids suppress bone formation in patients with colitis |
| author_sort |
ROBINSON, R. J. |
| journal |
Alimentary pharmacology & therapeutics |
| journalStr |
Alimentary pharmacology & therapeutics |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1997 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
ROBINSON, R. J. IQBAL, S. J. WHITAKER, R. P. |
| container_volume |
11 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
ROBINSON, R. J. |
| doi_str_mv |
10.1046/j.1365-2036.1997.123294000.x |
| author2-role |
verfasserin |
| title_sort |
rectal steroids suppress bone formation in patients with colitis |
| title_auth |
Rectal steroids suppress bone formation in patients with colitis |
| abstract |
Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. |
| abstractGer |
Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. |
| abstract_unstemmed |
Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
1 |
| title_short |
Rectal steroids suppress bone formation in patients with colitis |
| url |
http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x |
| remote_bool |
true |
| author2 |
IQBAL, S. J. WHITAKER, R. P. ABRAMS, K. MAYBERRY, F. |
| author2Str |
IQBAL, S. J. WHITAKER, R. P. ABRAMS, K. MAYBERRY, F. |
| ppnlink |
NLEJ243926529 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1046/j.1365-2036.1997.123294000.x |
| up_date |
2024-07-06T01:16:30.272Z |
| _version_ |
1803790414275149824 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242219195</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505185203.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1997 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.1997.123294000.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242219195</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">ROBINSON, R. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rectal steroids suppress bone formation in patients with colitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford BSL</subfield><subfield code="b">Blackwell Science</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: The aetiology of bone loss in inflammatory bowel disease is multifactorial, but oral corticosteroids are an important contributory factor. Rectally administered steroids are widely used in patients with distal disease, but very little is known about their effect on bone metabolism. The aim of this study was to investigate the effect of a standard course of rectal prednisolone on biochemical markers of bone turnover. Methods: In a longitudinal study of 10 patients, biochemical markers of bone turnover were measured before, during and after treatment with prednisolone metasulphobenzoate (Predfoam, Pharmax Ltd) 20 mg twice daily for 2 weeks. Bone formation markers measured were serum osteocalcin (BGP), bone-specific alkaline phosphatase (BALP) and procollagen carboxy-terminal propeptide (PICP). Urinary deoxypyridinoline (dPyr) was measured to assess bone resorption. Results: Disease activity scores improved during treatment (difference in mean Powell–Tuck score=2.3 (±3.1), 95% CI: 0.11–4.48, P=0.04). There was a significant fall in BALP (P=0.02) during treatment, and a rapid but non-significant fall in BGP (P=0.19). PICP (0.42), and urinary dPyr (0.30) did not change significantly during treatment. Conclusions: Following a standard 2-week course of rectal prednisolone metasulphobenzoate, we observed a significant fall in bone-specific alkaline phosphatase activity. These results suggest that bone formation is suppressed in patients with distal colitis treated with pharmacological doses of rectal steroids.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">IQBAL, S. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">WHITAKER, R. P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">ABRAMS, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">MAYBERRY, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">11(1997), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:1997</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.1997.123294000.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">1997</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399687 |